Today's Rundown Chugai ponies up $1B+ to combine R&D operations in Yokohama Novartis' asthma triplet beats GSK's Advair in phase 2 trial Amgen bids $167M to buy drug discovery shop Nuevolution Biotech builder ElevateBio reveals its first portfolio company: AlloVir Spire Health launches COPD study with its machine-washable wearable Featured Story | | | Wednesday, May 22, 2019 Chugai Pharmaceuticals is shelling out ¥127.3 billion on a new R&D site in Yokohama, where it will combine the work of two long-standing research labs in nearby cities. It will start building the new facility this August. |
|
|
Top Stories Wednesday, May 22, 2019 Novartis’ triple combination asthma candidate QVM149 has beaten GlaxoSmithKline’s Advair in a phase 2 trial. The study linked QVM149 to statistically significant improvements in lung function, leading Novartis to talk up its potential to improve outcomes in uncontrolled asthma. Wednesday, May 22, 2019 Amgen has offered $167 million to buy Nuevolution. The takeover will give Amgen control of a drug discovery platform that landed Nuevolution deals with leading companies plus a pipeline of early-stage cancer and inflammation programs. Wednesday, May 22, 2019 A week after launching with $150 million, ElevateBio is unveiling its first portfolio company: AlloVir, a biotech working on off-the-shelf cell therapies against several common viruses, including flu, respiratory syncytial virus and a type of herpes virus. Wednesday, May 22, 2019 Using an innovative wearable, Spire Health has launched a study to develop new digital biomarkers that can predict exacerbations—and potentially hospitalizations—in patients with severe chronic obstructive pulmonary disease. | This week's sponsor is ExL Events. | | | |
Resources Sponsored by: Catalent Download the executive summary to learn key considerations for a successful technology transfer for manufacturing drug products, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. Sponsored by: AlphaSense What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve? Sponsored by: JPEO-CBRND – Medical Countermeasure Systems MCS is currently seeking broad-based industry/academia collaboration on research and prototype work in technical areas related to developing medical countermeasures for the Joint Warfighter. Sponsored by: Outer Edge Technology Learn how the cloud can support the performance and security requirements for validated, mission-critical applications historically designed and implemented exclusively via on-premises deployment. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA Medical Sensors Design Conference June 25, 2019 | McEnery Convention Center | San Jose, CA Sensors Expo & Conference June 25-27, 2019 | McEnery Convention Center | San Jose, CA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 